Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Trevi Therapeutics Inc
TRVICurrent price
2.86 USD
-0.01 USD (-0.35%)
Last closed
2.86 USD
Company
www.trevitherapeutics.com
ISIN
US89532M1018
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
223 679 184 USD
Yield for 12 month
+107.25 %
1Y
3Y
5Y
10Y
15Y
TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Address: 195 Church Street, New Haven, CT, United States, 06510
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
9.11 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-123 000 USD
Last Year
-43 000 USD
Current Quarter
–
Last Quarter
-38 000 USD
Key Figures TRVI
1 year
3 years
5 years
10 years
EBITDA
-48 070 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-36.57 %
PEG Ratio
–
Return On Equity TTM
-59.65 %
Wall Street Target Price
9.11 USD
Revenue TTM
–
Book Value
0.78 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.44 USD
Diluted Eps TTM
-0.44 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics TRVI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TRVI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation TRVI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-4.9151
Price Book MRQ
3.5823
Financials TRVI
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TRVI
For 52 weeks
0.97 USD
4 USD
50 Day MA
3.15 USD
Shares Short Prior Month
1 509 256
200 Day MA
2.84 USD
Short Ratio
3.53
Shares Short
1 523 018
Short Percent
3.37 %
BeatStart